Anvisa has approved datopotamab deruxtecan (Datroway) for adults with advanced EGFR-mutated non-small cell lung cancer in Brazil, expanding targeted therapy options in one of oncology’s most active segments.
Anvisa has approved datopotamab deruxtecan (Datroway) for adults with advanced EGFR-mutated non-small cell lung cancer in Brazil, expanding targeted therapy options in one of oncology’s most active segments.
Brazil’s health regulator has approved five new semaglutide injection pens for diabetes treatment, intensifying competition against Novo Nordisk as the molecule’s patent expired in March 2026.
You must be logged in to post a comment.